Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Law MG, Achhra A, Deeks SG, Gazzard B, Migueles SA, Novak RM, Ristola M; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. Law MG, et al. Among authors: novak rm. HIV Med. 2015 Apr;16 Suppl 1(0 1):37-45. doi: 10.1111/hiv.12232. HIV Med. 2015. PMID: 25711322 Free PMC article. Clinical Trial.
Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group; Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, et al. HIV Med. 2015 Apr;16 Suppl 1(0 1):1-9. doi: 10.1111/hiv.12227. HIV Med. 2015. PMID: 25711317 Free PMC article. No abstract available.
Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.
MacArthur RD, Chen L, Peng G, Novak RM, van den Berg-Wolf M, Kozal M, Besch L, Yurik T, Schmetter B, Henley C, Dehlinger M; CPRCA 058 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. MacArthur RD, et al. Among authors: novak rm. HIV Clin Trials. 2004 Nov-Dec;5(6):361-70. doi: 10.1310/WEQG-QTHL-DL3X-FTXC. HIV Clin Trials. 2004. PMID: 15682349 Clinical Trial.
The Incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naïve participants started on three different antiretroviral therapy strategies.
Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf Mv, Peng G, Xiang Y, Baxter JD, Uy J, Telzak EE, Novak RM; Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Kozal MJ, et al. Among authors: novak rm. HIV Clin Trials. 2007 Nov-Dec;8(6):357-70. doi: 10.1310/hct0806-357. HIV Clin Trials. 2007. PMID: 18042501 Clinical Trial.
Virologic, immunologic, clinical, safety, and resistance outcomes from a long-term comparison of efavirenz-based versus nevirapine-based antiretroviral regimens as initial therapy in HIV-1-infected persons.
van den Berg-Wolf M, Hullsiek KH, Peng G, Kozal MJ, Novak RM, Chen L, Crane LR, Macarthur RD; CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA), and The International Network for Strategic Initiative in Global HIV Trials (INSIGHT). van den Berg-Wolf M, et al. Among authors: novak rm. HIV Clin Trials. 2008 Sep-Oct;9(5):324-36. doi: 10.1310/hct0905-324. HIV Clin Trials. 2008. PMID: 18977721 Clinical Trial.
Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study.
Pett SL, Kunisaki KM, Wentworth D, Griffin TJ, Kalomenidis I, Nahra R, Montejano Sanchez R, Hodgson SW, Ruxrungtham K, Dwyer D, Davey RT, Wendt CH; INSIGHT FLU003 Plus Study Group. Pett SL, et al. Open Forum Infect Dis. 2017 Oct 25;5(1):ofx228. doi: 10.1093/ofid/ofx228. eCollection 2018 Jan. Open Forum Infect Dis. 2017. PMID: 29322062 Free PMC article.
DNA methylation is associated with airflow obstruction in patients living with HIV.
Hernandez Cordero AI, Yang CX, Obeidat M, Yang J, MacIsaac J, McEwen L, Lin D, Kobor M, Novak R, Hudson F, Klinker H, Dharan N, Man SP, Sin DD, Kunisaki K, Leung J; INSIGHT START Pulmonary and Genomic Substudy Groups. Hernandez Cordero AI, et al. Thorax. 2021 May;76(5):448-455. doi: 10.1136/thoraxjnl-2020-215866. Epub 2020 Dec 18. Thorax. 2021. PMID: 33443234 Free PMC article. Clinical Trial.
Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium.
Brazier E, Ajeh R, Maruri F, Musick B, Freeman A, Wester CW, Lee MP, Shamu T, Crabtree Ramírez B, d'Almeida M, Wools-Kaloustian K, Kumarasamy N, Althoff KN, Twizere C, Grinsztejn B, Tanser F, Messou E, Byakwaga H, Duda SN, Nash D; International epidemiology Databases to Evaluate AIDS. Brazier E, et al. J Int AIDS Soc. 2022 Dec;25(12):e26036. doi: 10.1002/jia2.26036. J Int AIDS Soc. 2022. PMID: 36504431 Free PMC article.
Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).
Palella FJ Jr, Armon C, Buchacz K, Chmiel JS, Novak RM, D'Aquila RT, Brooks JT; HOPS Investigators. Palella FJ Jr, et al. Among authors: novak rm. J Antimicrob Chemother. 2014 Oct;69(10):2826-34. doi: 10.1093/jac/dku190. Epub 2014 Jun 16. J Antimicrob Chemother. 2014. PMID: 24942257
192 results